The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.
University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA.
Biochemical pharmacology 2012;83(8):1084-103.
Since cloning of the ATP-binding cassette (ABC) family member breast cancer resistance protein (BCRP/ABCG2) and its characterization as a multidrug resistance efflux transporter in 1998, BCRP has been the subject of more than two thousand scholarly articles. In normal tissues, BCRP functions as a defense mechanism against toxins and xenobiotics, with expression in the gut, bile canaliculi, placenta, blood-testis and blood-brain barriers facilitating excretion and limiting absorption of potentially toxic substrate molecules, including many cancer chemotherapeutic drugs. BCRP also plays a key role in heme and folate homeostasis, which may help normal cells survive under conditions of hypoxia. BCRP expression appears to be a characteristic of certain normal tissue stem cells termed "side population cells," which are identified on flow cytometric analysis by their ability to exclude Hoechst 33342, a BCRP substrate fluorescent dye. Hence, BCRP expression may contribute to the natural resistance and longevity of these normal stem cells. Malignant tissues can exploit the properties of BCRP to survive hypoxia and to evade exposure to chemotherapeutic drugs. Evidence is mounting that many cancers display subpopulations of stem cells that are responsible for tumor self-renewal. Such stem cells frequently manifest the "side population" phenotype characterized by expression of BCRP and other ABC transporters. Along with other factors, these transporters may contribute to the inherent resistance of these neoplasms and their failure to be cured.
2 Originating Grant
CULLEN, KEVIN J
8 August 2008 - 31 July 2016
NATIONAL CANCER INSTITUTE
ROSS, DOUGLAS D
1 May 1990 - 30 November 1999
NATIONAL CANCER INSTITUTE
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
D D RossLeukemia 2000;14(3):467-73.
L Austin Doyle; Douglas D RossOncogene 2003;22(47):7340-58.
P L Rachel Ee; Xiaolong He; Douglas D Ross; William T BeckMolecular cancer therapeutics 2004;3(12):1577-83.
Appears in this Publication
Author of this Publication